Replies to post #199 on Trillium Therapeutics Inc (TRIL)

[NY1972]

Hu5F9-G4 P1 data

The 1 mg/kg dose resulted in a mean RBC CD47 receptor occupancy of 91% ± 3% [95% CI 86 – 93%], indicating target saturation with no G3 anemia, and was selected as the Priming Dose.

16 patients have been enrolled, two patients (adenoid cystic ca) receiving weekly doses in Part A (0.1 mg/kg and 1 mg/kg) had stable disease for 16 and 8 months on continuous weekly drug dosing, respectively.

[jondoeuk]

For some reason a little bit of power goes to their heads